PDF(Pubmed)
Abstract：
Ovarian cancer (OC) is the most lethal gynecologic malignancy worldwide. Due to the lack of effective screening and early detection strategies, many patients with OC are diagnosed with advanced disease, where treatment is rarely curative. Moreover, OC is characterized by high intratumor heterogeneity, which represents a major barrier to the development of effective treatments. Conventional tumor biopsy and blood-based biomarkers, such as cancer antigen 125 (CA125), have different limitations. Liquid biopsy has recently emerged as an attractive and promising area of investigation in oncology, due to its minimally invasive, safe, comprehensive, and real-time dynamic nature. Preliminary evidence suggests a potential role of liquid biopsy to refine OC management, by improving screening, early diagnosis, assessment of response to treatment, detection, and profiling of drug resistance. The current knowledge and the potential clinical value of liquid biopsy in OC is discussed in this review to provide an overview of the clinical settings in which its use might support and improve diagnosis and treatment.
摘要：
卵巢癌（OC）是世界上最致命的妇科恶性肿瘤。由于缺乏有效的筛查和早期发现策略，许多OC患者被诊断为晚期疾病，治疗很少治愈的地方。此外，OC的特点是肿瘤内异质性高，这是有效治疗方法发展的主要障碍。常规肿瘤活检和血液生物标志物，如癌抗原125（CA125），有不同的局限性。液体活检最近已成为肿瘤学研究的一个有吸引力和有前途的领域，由于其微创性，安全,全面,和实时动态性质。初步证据表明液体活检对改善OC管理具有潜在作用，通过改进筛查，早期诊断,对治疗反应的评估，检测,和耐药性分析。本综述讨论了OC中液体活检的当前知识和潜在临床价值，以概述其使用可能支持和改善诊断和治疗的临床环境。
